Spatiotemporal mosaic self-patterning of pluripotent stem cells using CRISPR interference
- PMID: 30298816
- PMCID: PMC6177255
- DOI: 10.7554/eLife.36045
Spatiotemporal mosaic self-patterning of pluripotent stem cells using CRISPR interference
Abstract
Morphogenesis involves interactions of asymmetric cell populations to form complex multicellular patterns and structures comprised of distinct cell types. However, current methods to model morphogenic events lack control over cell-type co-emergence and offer little capability to selectively perturb specific cell subpopulations. Our in vitro system interrogates cell-cell interactions and multicellular organization within human induced pluripotent stem cell (hiPSC) colonies. We examined effects of induced mosaic knockdown of molecular regulators of cortical tension (ROCK1) and cell-cell adhesion (CDH1) with CRISPR interference. Mosaic knockdown of ROCK1 or CDH1 resulted in differential patterning within hiPSC colonies due to cellular self-organization, while retaining an epithelial pluripotent phenotype. Knockdown induction stimulates a transient wave of differential gene expression within the mixed populations that stabilized in coordination with observed self-organization. Mosaic patterning enables genetic interrogation of emergent multicellular properties, which can facilitate better understanding of the molecular pathways that regulate symmetry-breaking during morphogenesis.
Keywords: bio-engineering; developmental biology; human; morphogenesis; pluripotent stem cells; regenerative medicine; stem cells.
© 2018, Libby et al.
Conflict of interest statement
AL, DJ, PS, JM, FM, VW No competing interests declared, MM Currently an employee of Tenaya Therapeutics. BC On the Scientific Advisory Boards of: CODA Therapeutics, making therapies related to pain relief; Cellogy Inc., a cell dynamics measurement company; and Scientist.com, a scientific services company. Also a founder of Tenaya Therapeutics (https://www.tenayatherapeutics.com/), a company focused on finding treatments for heart failure, including the use of CRISPR interference to interrogate genetic cardiomyopathies. Holds equity in Tenaya, and Tenaya provides research support for heart failure-related research. TM A consultant for Tenaya Therapeutics.
Figures















References
Publication types
MeSH terms
Substances
Grants and funding
- LAI-C1408015/California Institute for Regenerative Medicine/International
- P01HL089707/NH/NIH HHS/United States
- R01 HL130533/HL/NHLBI NIH HHS/United States
- Instrumentation Grant, NIH S10 RR028962/NH/NIH HHS/United States
- R01 HL135358/HL/NHLBI NIH HHS/United States
- U01HL100406/NH/NIH HHS/United States
- T32 HD007470/HD/NICHD NIH HHS/United States
- R01HL130533/NH/NIH HHS/United States
- F31 HL140907/HL/NHLBI NIH HHS/United States
- P01 HL089707/HL/NHLBI NIH HHS/United States
- Center Core Grant, NIH P30 AI027763/NH/NIH HHS/United States
- U01 HL100406/HL/NHLBI NIH HHS/United States
- NSF-CBET 0939511/Emergent Behaviors of Integrated Cellular Systems/International
- R01 EY028249/EY/NEI NIH HHS/United States
- S10 RR028962/RR/NCRR NIH HHS/United States
- F31HL140907/HL/NHLBI NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous